Quantum-Enhanced Predictive Genomics Market Report 2026

The quantum-enhanced predictive genomics market size has grown exponentially in recent years. It will grow from $1.95 billion in 2025 to $2.61 billion in 2026 at a compound annual growth rate (CAGR) of 34%. The growth in the historic period can be attributed to advances in genomic sequencing technologies, growth in large-scale genomic datasets, early research adoption of quantum computing, increasing focus on personalized medicine, expansion of bioinformatics capabilities.

The quantum-enhanced predictive genomics market size is expected to see exponential growth in the next few years. It will grow to $8.36 billion in 2030 at a compound annual growth rate (CAGR) of 33.7%. The growth in the forecast period can be attributed to increasing availability of commercial quantum computing platforms, rising investment in precision medicine research, growing demand for predictive healthcare analytics, expansion of quantum machine learning applications, increasing collaboration between genomics and quantum technology firms. Major trends in the forecast period include increasing adoption of quantum-based genomic modeling, rising use of hybrid quantum-classical analytics, growing focus on high-dimensional biomarker discovery, expansion of cloud-based quantum genomics platforms, enhanced emphasis on predictive disease risk modeling.

The growing demand for personalized medicine is expected to drive the expansion of the quantum-enhanced predictive genomics market in the coming years. Personalized medicine involves customizing medical care, treatments, and preventive strategies based on an individual’s unique genetic, biological, and clinical characteristics. The rising interest in personalized medicine is attributed to improved treatment outcomes, as therapies tailored to a person’s genetic profile result in better efficacy and fewer side effects. Quantum-enhanced predictive genomics facilitates personalized medicine by enabling rapid analysis of complex genomic data, allowing clinicians to develop highly precise, individualized treatment and prevention plans. For example, in 2024, NHS England reported that its genomic medicine service conducted over 810,000 personalized genomic tests for patients, marking an 8% increase from 2023, reflecting the growing clinical demand for genomics-based care. As a result, the increasing demand for personalized medicine is expected to drive the growth of the quantum-enhanced predictive genomics market.

Key players in the quantum-enhanced predictive genomics market are concentrating on innovations such as high-throughput genomic data processing to accelerate the identification of genetic variations, enhance predictive accuracy in personalized medicine, and enable faster, more precise analysis of complex genomic datasets. High-throughput genomic data processing refers to the rapid, large-scale examination of genomic sequences using advanced computational techniques. For instance, in June 2025, Norma Group, a Germany-based developer and manufacturer of engineered and standardized joining and fluid-handling technology, partnered with Seoul National University Bundang Hospital (SNUBH) to implement quantum algorithms for large-scale genomic analysis. The initiative aims to accelerate the detection of genetic mutations through quantum-enhanced combinatorial optimization, improving both the speed and accuracy of genomic data processing compared to classical computing methods. Key applications include precision diagnostics, personalized treatment planning, and genetic risk assessment for conditions such as cancer and neurological disorders.

In August 2025, Quantinuum, a UK-based software company, collaborated with the Wellcome Sanger Institute to advance quantum computing applications in genomics. This partnership is part of the Sanger Institute’s Wellcome Leap Quantum for Bio (Q4Bio) challenge, a global program supporting research in quantum-based genomic analysis. The Sanger Institute, based in the UK, is focused on developing quantum-enhanced predictive genomics technologies.

Major companies operating in the quantum-enhanced predictive genomics market are Google LLC, Microsoft Corporation, Alibaba Group Holding Limited, Amazon Web Services, Inc., F. Hoffmann-La Roche AG, Accenture plc, IBM Corporation, Honeywell International Inc., Fujitsu Limited, Eviden, Xanadu Quantum Technologies Inc., Pasqal SA, Rigetti Computing, Inc., IonQ, Inc., D-Wave Systems Inc., Quantinuum, Atom Computing, Inc., Alice & Bob, QC Ware Corp., PsiQuantum, Inc., QuEra Computing, Inc., Quandela, Quantum Motion Ltd., Amazon.com, Inc., Intel Corporation, Cambridge Quantum Computing Ltd., Atos SE, NEC Corporation.

North America was the largest region in the quantum-enhanced predictive genomics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the quantum-enhanced predictive genomics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the quantum-enhanced predictive genomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the quantum-enhanced predictive genomics market by increasing costs of imported quantum computing hardware, specialized processors, cryogenic systems, and advanced data center infrastructure required for quantum-genomic analysis. Research institutions and biotechnology companies in North America and Europe are most affected due to reliance on globally sourced quantum components, while Asia-Pacific faces higher costs for expanding quantum cloud infrastructure. These tariffs are raising research and deployment expenses and slowing commercialization timelines. However, they are also encouraging domestic quantum hardware development, localized data center investments, and regional innovation ecosystems supporting long-term market growth.

The quantum-enhanced predictive genomics market research report is one of a series of new reports that provides quantum-enhanced predictive genomics market statistics, including quantum-enhanced predictive genomics industry global market size, regional shares, competitors with a quantum-enhanced predictive genomics market share, detailed quantum-enhanced predictive genomics market segments, market trends and opportunities, and any further data you may need to thrive in the quantum-enhanced predictive genomics industry. This quantum-enhanced predictive genomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Quantum-enhanced predictive genomics involves using quantum computing to examine complex genomic data, allowing for faster and more precise predictions of disease risk, treatment outcomes, and other health-related factors. It identifies patterns in large-scale genetic datasets that traditional methods might overlook, aiding biomarker discovery and personalized medicine.

The primary technologies in quantum-enhanced predictive genomics include quantum computing, quantum machine learning, quantum cryptography, and more. Quantum computing refers to advanced computational systems designed for rapid analysis and interpretation of intricate genomic datasets. These solutions can be implemented in cloud-based or on-premises settings, serving key users such as pharmaceutical and biotechnology companies, research institutions, healthcare providers, and other organizations involved in genomics and precision medicine.

The quantum-enhanced predictive genomics market consists of revenues earned by entities by providing services such as clinical decision support services, oncology-focused predictive genomics services, and multi-omics integration services. The market value includes the value of related goods sold by the service provider or included within the service offering. The quantum-enhanced predictive genomics market includes sales of quantum-powered epigenetic predictive tools, quantum-integrated personalized preventive health tools, and quantum-enhanced synthetic biology design platforms. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.